Company intelligence / Profile preview
GABA Therapeutics
Newport Beach, California, United Statesgabarx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
GABA Therapeutics has completed Phase 1 clinical trials for its lead compound GRX‑917—a deuterated analog of etifoxine—demonstrating favorable safety and tolerability. The company plans to initiate pivotal registration trials in generalized anxiety disorder in 2025. qEEG biomarkers confirmed target engagement and anxiolytic efficacy in early studies.
- Therapeutic areas
- EndocrinologyPsychiatryNeurology
- Modalities
- Small molecules (deuterated analogs of existing drugs; neurosteroid modulators)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Major partnership/ownership by atai Life Sciences N.V.No other major pharma partnerships disclosed.
Beyond the preview
Go deeper on GABA Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GABA Therapeutics.